Myeloma Cancer Multiple myeloma and malignant plasma cell neoplasms
Conditions
Interventions
Plasma exchange in addition to standard chemotherapy versus standard chemotherapy alone.
Added as of 10/12/2009:
Chemotherapy (ALL patients): two 4-day courses of dexa
Sponsors
Imperial College London (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with newly diagnosed myeloma and acute renal failure, aged 18 years or over Added as of 10/12/2009: 1. Newly diagnosed myeloma 2. Acute renal failure (creatinine greater than 500 mmol/l, urine output less than 400 ml/d or requiring dialysis) 3. Aged 18 years or over, either sex 4. Written informed consent 5. No previous chemotherapy for myeloma 6. No significant intrinsic renal disease unrelated to myeloma
Exclusion criteria
Exclusion criteria: Does not comply with above inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Added as of 10/12/2009: Proportion of patients alive and dialysis-independent at 100 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Added as of 10/12/2009: 1. To determine whether addition of plasma exchange to chemotherapy affects overall survival 2. To assess the impact of the addition of plasma exchange to chemotherapy on patients' quality of life 3. To assess the value of renal histology in predicting recovery of renal function 4. To assess the value of serum free light chain assay in determining response of the myeloma to chemotherapy and recovery of renal function in patients with renal failure | — |
Countries
England, United Kingdom
Outcome results
None listed